Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 677 press releases before 2019
-
US Appeals Court lifts temporary injunction against Hanmi's 505(b)2 NDA esomeprazole strontium product
-
AstraZeneca welcomes new arrivals as Alderley Park BioHub expands
-
Marketing Authorisation Application for naloxegol accepted by European Medicines Agency
-
Marketing Authorisation Application for olaparib accepted by European Medicines Agency
-
New hypoglycemia and pancreatitis subanalyses from the Onglyza® (saxagliptin) SAVOR cardiovascular outcomes trial presented at the 49th annual meeting of the European Association for the Study of Diabetes (EASD)
-
New Phase III data showed dapagliflozin significantly reduced HBA1C compared to placebo at 24 weeks in patients with type 2 diabetes inadequately controlled with the combination of metformin plus sulfonylurea
-
Fluenz Tetra, four-strain nasal spray vaccine, receives positive opinion in EU from CHMP for the prevention of seasonal influenza in children
-
FDA accepts new drug application for investigational compound Epanova for the treatment of severe hypertriglyceridaemia
-
US appeals court issues temporary injunction against Hanmi’s 505(b)2 NDA Esomeprazole Strontium
-
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
